Wilson C, Martin C, Winter M C
Weston Park Hospital, Sheffield Teaching Hospitals NHS Foundation Trust, Whitham Road, Sheffield, S10 2SJ, UK.
Medical School, University of Sheffield, Beech Hill Road, Sheffield, UK.
J Bone Oncol. 2019 Feb 19;15:100226. doi: 10.1016/j.jbo.2019.100226. eCollection 2019 Apr.
Adjuvant bisphosphonates (BPs) are recommended as part of routine early breast cancer treatment for many postmenopausal (PM) women within the past year. There is a paucity of 'real world' data on compliance and patient satisfaction with oral BPs in this population. The aim of our study was to investigate patient reported compliance and toxicity of these drugs in a retrospective cohort study.
413 patient were identified as receiving adjuvant oral BPs as part of their breast cancer treatment in the past 12 months from five NHS hospitals. The validated Osteoporosis Patient Treatment Satisfaction Questionnaire (OPSAT-Q) was sent to all suitable patients ( = 389).
295 (76%) of patients responded. Average age was median (range) 67 (35-89). The majority of patients had T1 (52%), N0 (61%) grade 2 (58%) ER positive (87%), HER2 negative (84%) breast cancer and were PM at diagnosis of breast cancer (93%). All patients had been prescribed at least 1 month of oral ibandronate 50 mg daily. Review of items rated on the 7-point scale (1 = very dissatisfied to 7 = very satisfied), the mean item scores ranged from 5.0 (lowest) for time required to take oral BPs, to 6.1 (highest) for how easy it is to remember to take the medication. <10% of patients were extremely bothered by heartburn or stomach upset. 16% of responders stopped oral BPs with 10% of those converting onto IV BPs.
Prevalence of severe side effects in a 'real world' population of PM women receiving adjuvant BPs is low and these drugs are generally well accepted and tolerated by patients.
在过去一年中，辅助性双膦酸盐（BPs）被推荐作为许多绝经后（PM）女性早期乳腺癌常规治疗的一部分。关于该人群口服BPs的依从性和患者满意度，缺乏“真实世界”的数据。我们研究的目的是在一项回顾性队列研究中调查患者报告的这些药物的依从性和毒性。
从五家国民保健服务（NHS）医院中确定了413名在过去12个月内接受辅助性口服BPs作为乳腺癌治疗一部分的患者。向所有合适的患者（n = 389）发送了经过验证的骨质疏松症患者治疗满意度问卷（OPSAT-Q）。
295名（76%）患者做出了回应。平均年龄为中位数（范围）67岁（35 - 89岁）。大多数患者患有T1期（52%）、N0期（61%）、2级（58%）、雌激素受体阳性（87%）、人表皮生长因子受体2阴性（84%）的乳腺癌，并且在诊断乳腺癌时已绝经（93%）。所有患者都被开了至少1个月的每日50毫克口服伊班膦酸钠。对7分制评分项目（1 = 非常不满意至7 = 非常满意）进行评估，平均项目得分范围从口服BPs所需时间的5.0（最低）到记住服药的难易程度的6.1（最高）。<10%的患者受到烧心或胃部不适的极大困扰。16%的应答者停止了口服BPs，其中10%转而使用静脉注射BPs。
在接受辅助性BPs的“真实世界”绝经后女性人群中，严重副作用的发生率较低，这些药物通常被患者很好地接受和耐受。
